Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells
Date
2003Author
Tonetti, D. A.Rubenstein, R.
DeLeon, M.
Zhao, H.
Pappas, S. G.
Bentrem, D. J.
Chen, B.
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Jordan, V. C.
Source
Journal of Steroid Biochemistry and Molecular BiologyVolume
87Pages
47-55Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
We previously reported stable transfection of estrogen receptor alpha (ERα) into the ER-negative MDA-MB-231 cells (S30) as a tool to examine the mechanism of action of estrogen and antiestrogens [J. Natl. Cancer Inst. 84 (1992) 580]. To examine the mechanism of ERβ action directly, we have similarly created ERβ stable transfectants in MDA-MB-231 cells. MDA-MB-231 cells were stably transfected with ERβ cDNA and clones were screened by estrogen response element (ERE)-luciferase assay and ERβ mRNA expression was quantified by real-time RT-PCR. Three stable MDA-MB-231/ERβ clones were compared with S30 cells with respect to their growth properties, ability to activate ERE- and activating protein-1 (AP-1) luciferase reporter constructs, and the ability to activate the endogenous ER-regulated transforming growth factor alpha (TGFα) gene. ERβ6 and ERβ27 clones express 300-400-fold and the ERβ41 clone express 1600-fold higher ERβ mRNA levels compared with untransfected MDA-MB-231 cells. Unlike S30 cells, 17β-estradiol (E2) does not inhibit ERβ41 cell growth. ERE-luciferase activity is induced six-fold by E2 whereas neither 4-hydroxytamoxifen (4-OHT) nor ICI 182, 780 activated an AP-1-luciferase reporter. TGFα mRNA is induced in response to E2, but not in response to 4-OHT. MDA-MB-231/ERβ clones exhibit distinct characteristics from S30 cells including growth properties and the ability to induce TGFα gene expression. Furthermore, ERβ, at least in the context of the MDA-MB-231 cellular milieu, does not enhance AP-1 activity in the presence of antiestrogens. In summary, the availability of both ERα and ERβ stable breast cancer cell lines now allows us to compare and contrast the long-term consequences of individual signal transduction pathways. © 2003 Elsevier Ltd. All rights reserved.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms
Liu, J.; Burdette, J. E.; Xu, H.; Gu, C.; Van Breemen, R. B.; Bhat, K. P. L.; Booth, N.; Constantinou, Andreas I.; Pezzuto, J. M.; Fong, H. H. S.; Farnsworth, N. R.; Bolton, J. L. (2001)Eight botanical preparations that are commonly used for the treatment of menopausal symptoms were tested for estrogenic activity. Methanol extracts of red clover (Trifolium pratense L.), chasteberry (Vitex agnus-castus ...
-
Article
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: A translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial
Skarlos, P.; Christodoulou, C.; Kalogeras, K. T.; Eleftheraki, A. G.; Bobos, M.; Batistatou, Anna; Valavanis, C.; Tzaida, O.; Timotheadou, E.; Kronenwett, R.; Wirtz, R. M.; Kostopoulos, I.; Televantou, D.; Koutselini, E.; Papaspirou, I.; Papadimitriou, C.; Pectasides, Dimitrios; Gogas, H.; Aravantinos, Gerasimos; Pavlidis, Nicholas; Arapantoni, P.; Skarlos, Dimosthenis V.; Fountzilas, George (2012)Purpose: It is well recognized that breast cancer is a heterogeneous disease. The purpose of the current study was to classify patients according to the immunohistochemical phenotype of their tumors in an effort to evaluate ...
-
Article
Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance
Pitta, Chara A.; Papageorgis, P.; Charalambous, Christina; Constantinou, Andreas I. (2013)The purpose of this work is to determine the molecular mechanisms underlying tamoxifen resistance. We show here that ER-β is epigenetically silenced in a cell line with acquired tamoxifen resistance (MCF-7/TAM-R) and this ...